I-Mab (IMAB)

1,6600 -0,0800 (-4,60%) Börsenschluss: 04:00PM EDT

I-Mab

2440 Research Boulevard
Suite 400
Rockville, MD 20850
United States
240 745 6330
https://ir.i-mabbiopharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Raj Kannan	CEO & Director	N/A	N/A	1964
Mr. Skelton Joseph	Chief Financial Officer	N/A	N/A	1991
Mr. Tianyi Zhang	Vice President of Investor Relations	N/A	N/A	N/A
Dr. Fernando J. Salle´s Ph.D.	Senior VP and Head of U.S. & EU Business Development	N/A	N/A	N/A
Claire Xu	Head of US site	N/A	N/A	N/A
Dr. Louie Naumovski M.D., Ph.D.	Interim Chief Medical Officer	N/A	N/A	N/A
Mr. Tyler Ehler	Senior Director of Investor Relations	N/A	N/A	N/A

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and internationally. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Corporate Governance

I-Mabs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.